Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVEL trial of Gardasil 9 after local treatment for high-grade cervical intraepithelial neoplasia
2018-004662-33Phase 3Unknown
- Sponsor
- Imperial College London
- Start
- Jul 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Imperial College London. Primary endpoint: Weighted composite efficacy endpoint at 24 months. Status: unknown.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2018-004662-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004662-33.